Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDXGet Free Report) have been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $62.17.

A number of brokerages have recently issued reports on CLDX. Wolfe Research initiated coverage on Celldex Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating and a $51.00 price objective for the company. Stifel Nicolaus began coverage on shares of Celldex Therapeutics in a research report on Tuesday, June 18th. They issued a “buy” rating and a $58.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday, June 18th. Finally, HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a report on Monday, June 3rd.

Read Our Latest Research Report on CLDX

Insider Buying and Selling

In related news, VP Elizabeth Crowley sold 30,000 shares of Celldex Therapeutics stock in a transaction on Friday, June 14th. The stock was sold at an average price of $34.87, for a total transaction of $1,046,100.00. Following the completion of the sale, the vice president now owns 9,074 shares of the company’s stock, valued at $316,410.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, VP Richard M. Wright sold 46,844 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $33.72, for a total transaction of $1,579,579.68. Following the transaction, the vice president now directly owns 20,833 shares of the company’s stock, valued at approximately $702,488.76. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Elizabeth Crowley sold 30,000 shares of Celldex Therapeutics stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $34.87, for a total transaction of $1,046,100.00. Following the transaction, the vice president now directly owns 9,074 shares in the company, valued at $316,410.38. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 266,332 shares of company stock valued at $9,155,821. Company insiders own 3.80% of the company’s stock.

Institutional Trading of Celldex Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Fisher Asset Management LLC boosted its position in Celldex Therapeutics by 4.6% during the 4th quarter. Fisher Asset Management LLC now owns 21,492 shares of the biopharmaceutical company’s stock valued at $852,000 after buying an additional 954 shares during the period. CANADA LIFE ASSURANCE Co raised its stake in shares of Celldex Therapeutics by 26.4% during the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock valued at $192,000 after acquiring an additional 955 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Celldex Therapeutics by 3.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,258 shares of the biopharmaceutical company’s stock worth $1,041,000 after purchasing an additional 962 shares during the period. Principal Financial Group Inc. grew its stake in shares of Celldex Therapeutics by 10.0% in the first quarter. Principal Financial Group Inc. now owns 13,153 shares of the biopharmaceutical company’s stock worth $552,000 after purchasing an additional 1,194 shares during the last quarter. Finally, Strs Ohio increased its holdings in Celldex Therapeutics by 92.9% during the 4th quarter. Strs Ohio now owns 2,700 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 1,300 shares during the period.

Celldex Therapeutics Stock Down 1.5 %

Celldex Therapeutics stock opened at $36.63 on Friday. The stock has a market cap of $2.41 billion, a PE ratio of -12.85 and a beta of 1.58. Celldex Therapeutics has a 12-month low of $22.11 and a 12-month high of $53.18. The business’s 50-day moving average price is $36.98 and its two-hundred day moving average price is $39.24.

Celldex Therapeutics (NASDAQ:CLDXGet Free Report) last announced its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.11. The company had revenue of $0.16 million during the quarter, compared to the consensus estimate of $1.30 million. Celldex Therapeutics had a negative net margin of 2,385.57% and a negative return on equity of 29.55%. As a group, analysts expect that Celldex Therapeutics will post -2.39 earnings per share for the current year.

About Celldex Therapeutics

(Get Free Report

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

Recommended Stories

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.